MARKET

QURE

QURE

Uniqure
NASDAQ
7.17
-0.14
-1.85%
After Hours: 7.41 +0.25 +3.42% 17:25 12/08 EST
OPEN
7.23
PREV CLOSE
7.30
HIGH
7.27
LOW
6.95
VOLUME
1.35M
TURNOVER
0
52 WEEK HIGH
24.27
52 WEEK LOW
5.49
MARKET CAP
342.57M
P/E (TTM)
-1.4943
1D
5D
1M
3M
1Y
5Y
Uniqure: Securities to be offered to employees in employee benefit plans
Press release · 1d ago
Weekly Report: what happened at QURE last week (1127-1201)?
Weekly Report · 6d ago
UniQure Says FDA Clears IND Application For AMT-191 Gene Therapy For Fabry Disease
NASDAQ · 11/29 13:41
uniQure wins FDA nod to study gene therapy for Fabry disease
Uniqure's amt-191 is a one-time gene therapy for a rare disorder called fabry disease. Dutch biotech intends to enroll patients in a phase 1/2 trial in h1 2024. Uniqure and its partner csl already have a liver-directed gene therapy approved for hemophilia.
Seeking Alpha · 11/29 12:40
Weekly Report: what happened at QURE last week (1120-1124)?
Weekly Report · 11/27 09:10
Weekly Report: what happened at QURE last week (1113-1117)?
Weekly Report · 11/20 09:11
Uniqure: Current report
Press release · 11/17 13:18
Weekly Report: what happened at QURE last week (1106-1110)?
Weekly Report · 11/13 09:10
More
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Webull offers Uniqure NV stock information, including NASDAQ: QURE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QURE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading QURE stock methods without spending real money on the virtual paper trading platform.